Jan 28, 2013

GlaxoSmithKline and the Hyderabad based Biologic E

Multinational drug-maker GlaxoSmithKline and the Hyderabad-based Biological E Limited have come together for early stage research and development of a six-in-one combination paediatric vaccine against polio and other infectious diseases.
The companies said they would form an equally-partnered venture to develop the vaccine that would help protect children in India and other developing countries. If approved, the vaccine could be a first of its kind, a GSK note said, as it would combine GSK’s injectable polio vaccine (IPV) and Biological E’s pentavalent vaccine for diphtheria, tetanus, whooping cough (whole-cell pertussis), hepatitis B, and Haemophilus influenzae type b.


The vaccine would enable fewer injections for children, thereby improving compliance in immunisation schedules. The fully liquid formulation of the vaccine also means it would be ready to use with no additional ingredients or materials required, freeing up space at local storage facilities.
The venture will bear the development costs for the candidate vaccine, which is expected to enter phase 1 development in the next two years. In phase 1 trials, the product is exposed for the first time to a small group of healthy human volunteers to evaluate the safety profile of the drug. A small initial cash investment will be made by both companies to cover start-up costs and subsequent development costs will be split equally, the note said.


Christophe Weber, President of GSK Vaccines, said the agreement was aligned to GSK’s vision of providing quality vaccines to those in need and by leveraging Biological E’s strengths, this particular vaccine had the potential to play a significant role in the fight against polio.
Vijay Kumar Datla, Chairman Biological E, said that they expect to leverage the partnership to accelerate the development of the hexavalent vaccine and make IPV accessible for developing countries in the post-eradication phase for polio.jyothi.datta@thehindu.co.in

Post Polio Litaff, Association A.C _APPLAC Mexico

Jan 23, 2013

Dr. Peter Salk, son of the late Dr. Jonas Salk

Ursinus talk reveals what influenced Dr. Salk, credited with eradicating polio

Audience members watch a movie with Dr. Jonas Salk, who asks the rhetorical question of whether we will be good ancestors. Photo by Phil Heil
Ursinus College’s Center for Science and the Common Good hosted the son of the man who discovered the vaccine for polio during an event Jan. 16.

Dr. Peter Salk, son of the late Dr. Jonas Salk, came to Ursinus to discuss his father’s work in the polio vaccine and his interest in humanity and how people came together to help each other when polio was killing thousands of people in the early 20th century.

The lecture began with Salk speaking about his father’s view on life and how when his father was a boy, he did not want to go into science.

“He wanted to find a way to help people,” Dr. Salk explained to the audience in the Kaleidoscope Building. According to Salk, science was the furthest thing from his father’s mind growing up. However, like most people, he decided to go where the money was, and thanks to the March of Dimes, the money for polio research was at an all-time high.

Post Polio Litaff, Association A.C _APPLAC Mexico

Polio Film


Entradas populares



México Post Polio Una Vida Un Camino Una Experiencia

Post Polio LITAFF A.C.

Postpoliolitaff.- Asociación Post Polio Litaff A.C Primera Organización oficial sobre Síndrome de Post Poliomielitis En México.

Polio y Efectos Secundarios SPP
- See more at: http://polioamigossinfronteras.blogspot.mx/#sthash.6PkHAkfM.dpuf


Salk Institute

Polio Video

Polio Lungs


Polio Reinders

March Of Dimes Polio History

Erradicación de La poliomielitis

Blog Archive

Search This Blog

No more Polio

Dr. Bruno